Why Former FDA Commissioner, Scott Gottlieb, Joined the Aetion Board | Carolyn Magil, CEO Aetion

By JESSICA DAMASSA, WTF HEALTH Big news from Aetion CEO, Carolyn Magil, as she talks about the addition of former FDA Commissioner, Scott Gottlieb, to her Board. WHOA. What a HUGE endorsement of support for what Aetion is building…which is what, exactly? Carolyn explains how the company is using real world data (any data outside of clinical trial data) to figure out how different people will react to the same drug. That means they’re using data from health insurance claims, EMRs, wearables, pharma registries, etc. to ultimately save the time, money, and headache of finding out which medicines will work best for which patients. What’s more? A priority for Aetion is helping bring to light how populations usually under-represented in clinical trials (women, seniors, kids) will react to certain treatments. Backed by $77M in funding, and now the former FDA head, tune in to find out what’s next for Aetion. Filmed at the HIMSS Health 2.0 Conference in Santa Clara, CA in September 2019. The post Why Former FDA Commissioner, Scott Gottlieb, Joined the Aetion Board | Carolyn Magil, CEO Aetion appeared first on The Health Care Blog.
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Tech Health Technology Jessica DaMassa WTF Health Aetion Carolyn Magil FDA Health 2.0 Pharma Scott Gottlieb Source Type: blogs